References
- Brown RB, Al‑Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
- Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of amyotrophic lateral sclerosis – United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:1285–9.
- Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49:431–8.
- US Food and Drug Administration. Update on Amyotrophic Lateral Sclerosis (ALS) Product Development [Internet]. US Food and Drug Administration; 2021. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/update-amyotrophic-lateral-sclerosis-als-product-development.
- Amylyx Pharmaceuticals. Amylyx Pharmaceuticals Submits New Drug Application (NDA) for AMX0035 for the Treatment of ALS [Internet]. Amylyx Pharmaceuticals; 2021. https://www.amylyx.com/2021/11/02/amylyx-pharmaceuticals-submits-new-drug-application-nda-for-amx0035-for-the-treatment-of-als/
- ClinicalTrials.gov. Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix) [Internet]. US National Library of Medicine; 2021. https://clinicaltrials.gov/ct2/show/NCT05021536
- Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919–30.
- Paganoni S, Hendrix S, Dickson SP, Knowlton N, Cohen J, Klee J, et al. Lower long-term risk of death or permanent ventilation and first hospitalization among participants with ALS Receiving AMX0035 in the CENTAUR Trial. 2021 Muscular Dystrophy Association (MDA) virtual clinical & scientific conference. 2021.
- ALS Association. ALS Association Applauds Amylyx’s AMX0035 Announcement, Urges Swift FDA Approval [Internet]. ALS Association; 2021. https://www.als.org/stories-news/als-association-applauds-amylyxs-amx0035-announcement-urges-swift-fda-approval
- Isakov L, Lo AW, Montazerhodjat V. Is the FDA too conservative or too aggressive?: A Bayesian decision analysis of clinical trial design. J Econom. 2019;211:117–36.
- US Food and Drug Administration. Guidance for industry: Fast track drug development programs – designation, development, and application review [Internet]. US Food and Drug Administration; 2006. https://permanent.fdlp.gov/LPS113471/UCM079736.pdf
- US Food and Drug Administration. Guidance for industry: Expedited programs for serious conditions – drugs and biologics [Internet]. US Food and Drug Administration; 2018. https://www.fda.gov/media/86377/download
- Greener M. Drug safety on trial. EMBO Rep. 2005;6:202–4.
- Aronson JK. Drug withdrawals because of adverse effects. In: Aronson JK, editor. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Oxford: Elsevier; 2008. p. xxxi–v.
- McNaughton R, Huet G, Shakir S. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. BMJ Open. 2014;4:e004221.
- ProCon.org. 35 FDA-approved prescription drugs later pulled from the market [Internet]. ProCon.org; 2014. https://www.procon.org/35-prescription-drugs-pulled-from-the-market/
- Montazerhodjat V, Chaudhuri SE, Sargent DJ, Lo AW. Use of Bayesian decision analysis to minimize harm in patient-centered randomized clinical trials in oncology. JAMA Oncol. 2017;3:e170123.
- Chaudhuri SE, Lo AW, Xiao D, Xu Q. Bayesian adaptive clinical trials for anti-infective therapeutics during epidemic outbreaks. Harvard Data Sci Rev 2020;Special Issue.
- Hauber B, Mange B, Zhou M, Chaudhuri S, Benz HL, Caldwell B, et al. Parkinson’s patients’ tolerance for risk and willingness to wait for potential benefits of novel neurostimulation devices: a patient-centered threshold technique study. MDM Policy Pract. 2021;6:2381468320978407.
- Chaudhuri SE, Ho MP, Irony T, Sheldon M, Lo AW. Patient-centered clinical trials. Drug Discov Today. 2018;23:395–401.
- Chaudhuri SE, Lo AW. Financially adaptive clinical trials via option pricing analysis. J Econom 2020;
- Chaudhuri SE, Lo AW. Incorporating patient preferences via Bayesian decision analysis. Clin J Am Soc Nephrol. 2021;16:639–41.
- Elia AE, Lalli S, Monsurrò MR, Sagnelli A, Taiello AC, Reggiori B, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23:45–52.
- GBD 2016 Motor Neuron Disease Collaborators. Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17:1083–97.
- Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141–5.
- Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68.
- Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017;7:61–70.